GFM
SLN icon

GF Fund Management’s Silence Therapeutics SLN Stock Holding History

GF Fund Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7K Sell
975
-72
-7% -$507 ﹤0.01% 533
2026
Q1 		$5.52K Buy
1,047
+125
+14% +$688 ﹤0.01% 602
2025
Q4 		$5.61K Sell
922
-56
-6% -$359 ﹤0.01% 619
2025
Q3 		$5.08K Sell
978
-187
-16% -$1.04K ﹤0.01% 609
2025
Q2 		$6.76K Hold
1,165
– – ﹤0.01% 606
2025
Q1 		$3.29K Buy
1,165
+178
+18% +$869 ﹤0.01% 638
2024
Q4 		$6.79K Buy
+987
New +$12.7K ﹤0.01% 592

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GF Fund Management's SLN Position: Q2 2026 in Review

GF Fund Management reduced its Silence Therapeutics (SLN) stake by 6.9% in Q2 2026, selling an estimated $507 and leaving 975 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #533.

GF Fund Management first reported a position in SLN in Q4 2024 and has held it in 7 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • GF Fund Management held 975 shares of Silence Therapeutics worth $10.7K as of Q2 2026.
  • GF Fund Management sold 72 Silence Therapeutics shares in Q2 2026, an estimated $507.
  • Silence Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #533 holding.
  • GF Fund Management first reported a position in Silence Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.